{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:48:12Z","timestamp":1761562092642},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/bjc.2016.82","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T23:22:20Z","timestamp":1459466540000},"page":"863-871","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study"],"prefix":"10.1038","volume":"114","author":[{"given":"W","family":"Janni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Rack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Jueckstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Wischnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Annecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Huober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Zwingers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T W P","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"BFbjc201682_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"O Abe","year":"2005","unstructured":"Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, Sugimachi K, Tominaga T, Uchino J, Yoshida M, Haybittle JL, Davies C, Harvey VJ, Holdaway TM, Kay RG, Mason BH, Forbes JF, Wilcken N, Gnant M, Jakesz R, Ploner M, Yosef HMA, Focan C, Lobelle JP, Peek U, Oates GD, Powell J, Durand M, Mauriac L, Di Leo A, Dolci S, Piccart MJ, Masood MB, Parker D, Price JJ, PSGJ Hupperets, Jackson S, Ragaz J, Berry D, Broadwater G, Cirrincione C, Muss H, Norton L, Weiss RB, Abu-Zahra HT, Portnoj SM, Baum M, Cuzick J, Houghton J, Riley D, Gordon NH, Davis HL, Beatrice A, Mihura J, Naja A, Lehingue Y, Romestaing P, Dubois JB, Delozier T, Mace-Lesec\u2019h J, Rambert P, Andrysek O, Barkmanova J, Owen JR, Meier P, Howell A, Ribeiro GC, Swindell R, Alison R, Boreham J, Clarke M, Collins R, Darby S, Elphinstone P, Evans V, Godwin J, Gray R, Harwood C, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Mead G, Peto R, Wang Y, Albano J, de Oliveira CF, Gervasio H, Gordilho J, Johansen H, Mouridsen HT, Gelman RS, Harris JR, Henderson IC, Shapiro CL, Andersen KW, Axelsson CK, Blichert-Toft M, Moller S, Overgaard J, Overgaard M, Rose C, Cartensen B, Palshof T, Trampisch HJ, Dalesio O, de Vries EGE, Rodenhuis S, van Tinteren H, Comis RL, Davidson NE, Robert N, Sledge G, Tormey DC, Wood W, Cameron D, Chetty U, Forrest P, Jack W, Rossbach J, Klijn JGM, Treurniet-Donker AD, van Putten WLJ, Costa A, Veronesi U, Bartelink H, Duchateau L, Legrand C, Sylvester R, van der Hage JA, van de Velde CJH, Cunningham MP, Catalano R, Creech RH, Bonneterre J, Fargeot P, Fumoleau P, Kerbrat P, Namer M, Jonat W, Kaufmann M, Schumacher M, von Minckwitz G, Bastert G, Rauschecker H, Sauer R, Sauerbrei W, Schauer A, de Schryver A, Vakaet L, Belfiglio M, Nicolucci A, Pellegrini F, Sacco M, Valentini M, McArdle CS, Smith DC, Galligioni E, Boccardo F, Rubagotti A, Dent DM, Gudgeon CA, Hacking A, Erazo A, Medina JY, Izuo M, Morishita Y, Takei H, Fentiman IS, Hayward JL, Rubens RD, Skilton D, Graeff H, Janicke F, Meisner C, Scheurlen H, von Fournier D, Dafni U, Fountzilas G, Klefstrom P, Blomqvist C, Saarto T, Margreiter R, Asselain B, Salmon RJ, Vilcoq JR, Arriagada R, Hill C, Laplanche A, Le MG, Spielmann M, Bruzzi P, Montanaro E, Rosso R, Sertoli MR, Venturini M, Amadori D, Benraadt J, Kooi M, van de Velde AO, van Dongen JA, Vermorken JB, Castiglione M, Cavalli F, Coates A, Collins J, Gelber RD, Goldhirsch A, Lindtner J, Price KN, Rudenstam CM, Senn HJ, Bliss JM, Chilvers CED, Coombes RC, Hall E, Marty M, Borovik R, Brufman G, Hayat H, Robinson E, Wigler N, Bonadonna G, Camerini T, De Palo G, Del Vecchio M, Formelli F, Valagussa P, Martoni A, Pannuti F, Cocconi G, Colozza A, Camisa R, Aogi K, Takashima S, Ikeda T, Inokuchi K, Sawa K, Sonoo H, Korzeniowski S, Skolyszewski J, Ogawa M, Yamashita J, Bonte J Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687\u20131717.","journal-title":"Lancet"},{"key":"BFbjc201682_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-011-1562-7","volume":"128","author":"JM Albert","year":"2011","unstructured":"Albert JM, Buzdar AU, Guzman R, Allen PK, Strom Ea, Perkins GH, Woodward Wa, Hoffman KE, Tereffe W, Hunt KK, Buchholz Ta, Oh JL (2011) Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) vs paclitaxel and FAC (TFAC) in patients with operable breast cancer: Impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128: 421\u2013427.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbjc201682_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","volume":"28","author":"M Burnell","year":"2010","unstructured":"Burnell M, Levine MN, Chapman JW, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, Brien PO, Shepherd LE (2010) Cyclophosphamide, epirubicin, and fluorouracil vs dose-dense epirubicin and cyclophosphamide followed by paclitaxel vs doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28: 77\u201382.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/annonc\/mdl238","volume":"17","author":"M Clarke","year":"2006","unstructured":"Clarke M (2006) Meta-analyses of adjuvant therapies for women with early breast cancer: The Early Breast Cancer Trialists\u2019 Collaborative Group overview. Ann Oncol 17: 59\u201362.","journal-title":"Ann Oncol"},{"key":"BFbjc201682_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1634\/theoncologist.2011-0442","volume":"17","author":"B Coudert","year":"2012","unstructured":"Coudert B, Asselain B, Campone M, Spielmann M, Machiels J-P, P\u00e9nault-Llorca F, Serin D, L\u00e9vy C, Romieu G, Canon J-L, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard J-C, Martin A-L, Roch\u00e9 H (2012) Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 17: 900\u2013909.","journal-title":"Oncologist"},{"key":"BFbjc201682_CR6","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay M-A, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR (2011) Phase III study of doxorubicin\/cyclophosphamide with concomitant vs sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29: 3877\u20133884.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR7","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2008.21.4791","volume":"27","author":"L Gianni","year":"2009","unstructured":"Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27: 4798\u20134808.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976\u2013983.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR9","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25: 2127\u20132132.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2007.11.3787","volume":"26","author":"M De Laurentiis","year":"2008","unstructured":"De Laurentiis M, Cancello G, D\u2019Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26: 44\u201353.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodr\u00edguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay M-A, Wilson V, Rupin M, Hou\u00e9 V, Vogel C (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14: 72\u201380.","journal-title":"Lancet Oncol"},{"key":"BFbjc201682_CR12","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23: 3686\u20133696.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR13","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla J-P, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302\u20132313.","journal-title":"N Engl J Med"},{"key":"BFbjc201682_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Mart\u00edn","year":"2008","unstructured":"Mart\u00edn M, Rodr\u00edguez-Lescure \u00c1, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Mun\u00e1rriz B, Rodr\u00edguez Ca, Crespo C, De Alava E, L\u00f3pez Garc\u00eda-Asenjo JA, Guiti\u00e1n MD, Almenar S, Gonz\u00e1lez-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Segu\u00ed MA, Mayordomo JI, Ant\u00f3n A, Baena JM, Plazaola A, Modolell A, Pelegr\u00ed A, Mel JR, Aranda E, Adrover E, \u00c1lvarez JV, Garc\u00eda Puche JL, S\u00e1nchez-Rovira P, Gonzalez S, L\u00f3pez-Vega JM (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100: 805\u2013814.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc201682_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12094-009-0309-y","volume":"11","author":"M Mart\u00edn-Jim\u00e9nez","year":"2009","unstructured":"Mart\u00edn-Jim\u00e9nez M, Rodr\u00edguez-Lescure A, Ruiz-Borrego M, Segu\u00ed-Palmer M-A, Brosa-Riestra M (2009) Cost-effectiveness analysis of docetaxel (Taxotere) vs 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol 11: 41\u201347.","journal-title":"Clin Transl Oncol"},{"key":"BFbjc201682_CR16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","volume":"385","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nistic\u00f2 C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial. Lancet (London, England) 385: 1863\u20131872.","journal-title":"Lancet (London, England)"},{"key":"BFbjc201682_CR17","doi-asserted-by":"publisher","first-page":"404396","DOI":"10.1155\/2013\/404396","volume":"2013","author":"HR Mirzaei","year":"2013","unstructured":"Mirzaei HR, Sabet Rasekh P, Nasrollahi F, Sabet Rasekh P, Akbari Tirabad Z, Moein HR, Ghaffari Pour T, Hajian P (2013) Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer. Int J Breast Cancer 2013: 404396.","journal-title":"Int J Breast Cancer"},{"key":"BFbjc201682_CR18","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","volume":"28","author":"V Moebus","year":"2010","unstructured":"Moebus V, Jackisch C, Lueck HJ, Du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, Von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28: 2874\u20132888.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/annonc\/mdu186","volume":"25","author":"U Nitz","year":"2014","unstructured":"Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Scholz M, Lisboa B, Mohrmann S, M\u00f6bus V, Augustin D, Hoffmann G, Weiss E, B\u00f6hmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, J\u00e4nicke F, Wallwiener D, Harbeck N, Kuhn W (2014) Final analysis of the prospective WSG-AGO EC-Doc vs FEC phase III trial in intermediate-risk (pN1) early breast cancer: Efficacy and predictive value of Ki67 expression. Ann Oncol 25: 1551\u20131557.","journal-title":"Ann Oncol"},{"key":"BFbjc201682_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K, Anderson S, Arriagada R, Barlow W, Bliss J, Buyse M, Cameron D, Carrasco E, Correa C, Coates A, Collins R, Costantino J, Cuzick J, Davidson N, Davies K, Delmestri A, Dowsett M, Elphinstone P, Evans V, Ewertz M, Gelber R, Gettins L, Geyer C, Goldhirsch A, Gregory C, Hayes D, Hill C, Ingle J, Jakesz R, James S, Kaufmann M, Kerr A, MacKinnon E, McHugh T, Norton L, Ohashi Y, Paik S, Perez E, Pierce L, Pruneri G, Raina V, Ravdin P, Robertson J, Rutgers E, Shao YF, Valagussa P, Viale G, Whelan T, Winer E, Wood W (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379: 432\u2013444.","journal-title":"Lancet"},{"key":"BFbjc201682_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-009-0468-0","volume":"119","author":"A Polyzos","year":"2010","unstructured":"Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D (2010) FEC vs sequential docetaxel followed by epirubicin\/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119: 95\u2013104.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbjc201682_CR22","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roch\u00e9","year":"2006","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Souli\u00e9 P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Gen\u00e8ve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial. J Clin Oncol 24: 5664\u20135671.","journal-title":"J Clin Oncol"},{"key":"BFbjc201682_CR23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.breast.2013.04.019","volume":"22","author":"G Sanna","year":"2013","unstructured":"Sanna G, Pestrin M, Zafarana E, Biagioni C, Cavaciocchi D, Turner N, Di Leo A, Biganzoli L (2013) Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients. Breast 22: 926\u2013932.","journal-title":"Breast"},{"key":"BFbjc201682_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273\u20131283.","journal-title":"N Engl J Med"},{"key":"BFbjc201682_CR25","unstructured":"US Department of Health and Human Services, Food and Drug Administration (2007) Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Available from \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071590.pdf\n                    \n                  ."},{"key":"BFbjc201682_CR26","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdr412","volume":"23","author":"P Vici","year":"2012","unstructured":"Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di benedetto A, Mottolese M, Colucci G, Lopez M (2012) A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) vs docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Ann Oncol 23: 1121\u20131129.","journal-title":"Ann Oncol"},{"key":"BFbjc201682_CR27","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R (2011) Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7: 214\u2013220.","journal-title":"Curr Cardiol Rev"},{"key":"BFbjc201682_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S1470-2045(10)70025-5","volume":"11","author":"H Wildiers","year":"2010","unstructured":"Wildiers H, Forceville K, Paridaens R, Joensuu H (2010) Taxanes and anthracyclines in early breast cancer: which first? Lancet Oncol 11: 219\u2013220.","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201682","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:36:52Z","timestamp":1684417012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFbjc201682"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.82","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,31]]},"assertion":[{"value":"24 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WJ received research grants from Novartis, GSK, Amgen, Eisai, Roche, Teva, Pierre Fabre, and Janssen Diagnostics. BR received research grants from Sanofi-Aventis, Astra-Zeneca, Amgen, and Novartis and is on the advisory board of Amgen and Novartis. JH is on the advisory board of Sanofi-Aventis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}